Results 181 to 190 of about 2,641,102 (341)

Patient Selection for Deep Brain Stimulation for Parkinson’s Disease----A Very Convenient Tool [PDF]

, 2019
Amit Kumar Ghosh
openalex   +1 more source

Diaries or questionnaires for collecting self-reported healthcare utilisation and patient cost data? CHERE Project Report No 20 [PDF]

The literature comparing diaries and questionnaires was reviewed in order to identify the most appropriate method of collecting patient self-reported data, on health service utilisation and out-ofpocket costs, for a longitudinal study.
Ajsa Mahmic, Emily Lancsar, Jane Hall, Madeleine King, Patsy Kenny, Rob Anderson   +5 more
core  

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

A data-driven analysis of patient selection for xenotransplant human clinical trials. [PDF]

PLoS One
Ata B, Montgomery RA, Ozyoruk YN, Parent B, Schold JD.   +4 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Patient Selection for Transcatheter Tricuspid Valve Intervention: Not Too Early, Not Too Late. [PDF]

Struct Heart
von Stein J, von Stein P, Alu MC, Scotti A, Ho EC, Granada JF, Latib A.   +6 more
europepmc   +1 more source

Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

, 2021
Chang Dy, Ma Wl, Lu YS
openalex   +1 more source

ICL Explant Due to Ocular Hypertension, Reduced Endothelial Cell Count and Anterior Sub Capsular Cataract Due to Patient Selection Error

, 2023
Gonzalez AL
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

ECMO in Refractory Septic Shock: Patient Selection, Timing and Hemodynamic Targets. [PDF]

J Clin Med
Torre DE, Pirri C.
europepmc   +1 more source